Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. on Feb. 12, 2026, for an initial $525,000 that can be increased by up to $975,000 with mutual consent. The note is secured by a lien on Lifeward’s cash, carries 24% annual interest, and matures on the earlier of Aug. 12, 2026 or failure to obtain required shareholder approvals for related transactions. Lifeward also has an earlier $3.0 million secured promissory note outstanding with Oramed Ltd., and any collateral proceeds would be applied ratably to both notes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000578), on February 19, 2026, and is solely responsible for the information contained therein.
Comments